Since my previous review, Ardelyx stock has risen over 100%, driven by promising developments in its drug portfolio.Ardelyx raised U.S. revenue forecasts for Ibsrela in IBS-C to $1 billion, targeting ...
Source LinkSince my previous review, Ardelyx stock has risen over 100%, driven by promising developments in its drug portfolio.Ardelyx raised U.S. revenue forecasts for Ibsrela in IBS-C to $1 billion, targeting ...
Source Link
Comments